All healthy donors were subjects with no history of autoimmune disease. PBMCs, pleural effusions, or ascites from cancer patients were collected before and after local administration of OK-432 based on the protocol approved by the Human Ethics Committees of Mie University Graduate School of Medicine and Nagasaki University Graduate School of Medicine. PBMCs from esophageal cancer PD-0332991 concentration patients enrolled in a clinical trial of CHP-NY-ESO-1 and CHP-HER2

vaccination with OK-432 [47] (Supporting Information Fig. 1) were collected based on the protocol approved by the Human Ethics Committees of Mie University Graduate School of Medicine and Kitano Hospital. The clinical trial was conducted in full conformity with the current version of the Declaration of Helsinki and was registered as NCT00291473 of Clinical Galunisertib mw Trial. gov, and 000001081 of UMIN Clinical Trial Registry. All samples were collected after written informed consent. Synthetic peptides of NY-ESO-11–20 (MQAEGRGTGGSTGDADGPGG), NY-ESO-111–30 (STGDADGPGGPGIPDGPGGN), NY-ESO-121–40 (PGIPDGPGGNAGGPGEAGAT), NY-ESO-131–50 (AGGPGEAGATGGRGPRGAGA), NY-ESO-141–60 (GGRGPRGAGAARASGPGGGA), NY-ESO-151–70 (ARASGPGGGAPRGPHGGAAS), NY-ESO-161–80 (PRGPHGGAASGLNGCCRCGA), NY-ESO-171–90 (GLNGCCRCGARGPESRLLEF), NY-ESO-181–100 (RGPESRLLEFYLAMPFATPM), NY-ESO-191–110 (YLAMPFATPMEAELARRSLA),

NY-ESO-1101–120 (EAELARRSLAQDAPPLPVPG), NY-ESO-1111–130 (QDAPPLPVPGVLLKEFTVSG), NY-ESO-1119–143 (PGVLLKEFTVSGNILTIRLTAADHR), NY-ESO-1131–150 (NILTIRLTAADHRQLQLSIS), NY-ESO-1139–160 (AADHRQLQLSISSCLQQLSLLM), NY-ESO-1151–170 (SCLQQLSLLMWITQCFLPVF), NY-ESO-1161–180 (WITQCFLPVFLAQPPSGQRR), and HIV P1737–51 (ASRELERFAVNPGLL) [48] were obtained from Invitrogen (Carlsbad, CA, USA). Recombinant NY-ESO-1 protein was prepared using similar procedures

as described previously [49]. OK-432 was purchased from Chugai Pharmaceutical (Tokyo, Japan). LPS (Escherichia aminophylline coli 055:B5) was obtained from Sigma (St. Louis, MO, USA). Purified and FITC-conjugated anti-IL-12 (C8.6; mouse IgG1), purified anti-IL-6 (MQ2–13A5; rat IgG1), purified anti-IFN-γ (NIB42; mouse IgG1), purified anti-IL-23 (HNU2319; mouse IgG1), PE-conjugated anti-CD20 (2H7; mouse IgG2b) and PE-conjugated anti-CD56 (MEM188; mouse IgG2a) Abs were purchased from eBioscience (San Diego, CA, USA). Purified anti-IL-1β Ab (8516; mouse IgG1) was purchased from R&D Systems (Minneapolis, MN, USA). PE-conjugated anti-CD14 (MϕP9; mouse IgG2b), PE-conjugated anti-CD45RA (HI100; mouse IgG2b), PerCP-conjugated anti-CD4 (RPA-T4; mouse IgG1), and FITC-conjugated anti-CD4 (RPA-T4; mouse IgG1), Foxp3 (259D; mouse IgG1), and CD45RO (UCHL1; mouse IgG2a) Abs were purchased from BD Biosciences (Franklin Lakes, NJ, USA). PerCP-Cy5.5-conjugated anti-CD11c Ab (3.9; mouse IgG1) was obtained from Biolegend (San Diego CA, USA).